

REMARKS/ARGUMENTS

After entry of this paper, claims 5 and 30-41 are pending and are elected in response to the outstanding restriction requirement. Claims 7, 11, 21, and 23 are canceled as being drawn to non-elected subject matter. Claims 3-4, 6, 10, 12-20, 22 and 24-29 are cancelled. Applicants reserve the right to pursue non-elected, canceled claims 7, 11, 21, and 23 and any other non-elected subject matter canceled from this application in a divisional application.

Claim 5 is amended to clarify the invention. New claims 30-41 are supported in the original specification and claims as provided in the attached table and elsewhere in the specification. No new matter is added by these amendments.

New Claim No.	Support
30	Pg. 4, lines 17, 33-34; pg. 5, line 7
31	Original claim 3
32	Original claim 8
33	Original claim 10
34	Pg. 43, line 19
35	Pg. 9, line 19
36	Pg. 5, lines 4-10
37	Pg. 5, lines 4-10
38	Pg. 43, lines 17-18; Table 5
39	Original claim 9
40	Pg. 5, lines 4-10
41	Pg. 43, lines 17-18; Table 5

Restriction Requirement

The Examiner restricted the claims into four (4) groups and required election of the claims of one group. The Examiner also required an identification of the claims encompassing the elected invention.

As noted above, Applicants elected the claims of Group I, *i.e.*, claims 3, 5, 8-10, and 24-29, (now claims 5 and 30-41) drawn to a method for detecting or screening for endocrine cancer.

Examiner's Comments Regarding Chang

The Examiner asserted that Chang et al. (British Journal of Cancer, May 2002, Vol. 86, pages 1457-1464) reads on claim 21.

Since Applicants did not elect the claims of Group IV in the present Response, which includes claim 21, Applicants reserve the right to provide comments on the teachings of Chang regarding its relevance only to claim 21 if this claim is formally rejected in an Office Action issued in a later filed divisional application.

Information Disclosure Statement

Applicants request that the Examiner consider the documents cited in the second Information Disclosure Statement submitted herewith.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON & HOWSON_{LLP}
Attorneys for Applicants

By: Mary E. Bak
Mary E. Bak
Registration No. 31,215
Suite 210
501 Office Center Drive
Fort Washington, PA 19034
Telephone: 215-540-9200
Telefacsimile: 215-540-5818

December 22, 2006